Ecoza Foam
Generic name:econazole nitrate
Dosage form: aerosol, foam
Drug class:Topical antifungals
Medically reviewed by Drugs.com. Last updated on Oct 22, 2021.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
Indications and Usage for Ecoza Foam
Ecoza isindicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.
Ecoza Foam Dosage and Administration
Ecoza is for topical use only. It is not for oral, ophthalmic, or intravaginal use.
Ecoza should be applied to cover affected areas once daily for 4 weeks.
Dosage Forms and Strengths
Topical foam, 1%. Each gram contains 10 mg of econazole nitrate in a white to off-white foam.
Contraindications
None.
Warnings and Precautions
Flammability
Ecoza is flammable. Avoid heat, flame, and smoking during and immediately following application. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty. Do not store in direct sunlight.
6. ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two double-blind, vehicle-controlled clinical trials, 495 subjects with interdigital tinea pedis applied Ecoza or vehicle once daily for approximately 28 days (246 subjects were exposed to Ecoza and 249 were exposed to vehicle). During clinical trials with Ecoza, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects ...